Walgreens Boots Alliance, Inc. (NASDAQ:WBA) shares edged slightly higher on Tuesday.
The agency’s specialty pharmacy arm introduced a big enlargement of its drug distribution network.
The corporate revealed that Walgreens Specialty Pharmacy has broadened its restricted distribution drug (LDD) portfolio to cowl 265 therapies, strengthening its function as one of the vital intensive specialty pharmacy networks within the U.S.
Additionally Learn: Costco Refuses To Stock Abortion Pill Mifepristone, Pointing To ‘Low Demand’ As Activist Groups Step Up Pressure On Retail Giants
LDDs are extremely regulated medicines distributed via chosen specialty pharmacies, usually involving advanced regimens, excessive prices, or particular dealing with necessities.
In contrast to pharmacies linked to pharmacy profit managers, Walgreens Specialty Pharmacy operates independently, which permits it to work flexibly with insurers, pharmaceutical producers, healthcare suppliers, and different companions.
This construction makes it doable to increase its collaborations with out being restricted by direct PBM ties.
“Because the restricted distribution drug community continues to develop, our specialty pharmacy groups throughout the nation are geared up to help producers in getting their medicines to sufferers who want it most,” stated Tracey James, RPh, chief working officer of Walgreens Specialty Pharmacy. She emphasised that independence helps the corporate have interaction broadly throughout the healthcare system.
Specialty drugs has develop into one of many fastest-growing healthcare sectors, with roughly three-quarters of newly developed medication falling into this class.
To deal with these challenges, Walgreens employs a nationwide crew of pharmacists, nurses, affected person advocates, and insurance coverage consultants devoted to supporting sufferers with distinctive circumstances and complicated therapy wants.
Among the many therapies added in 2025 are Yeztugo (lenacapavir) from Gilead Sciences, Inc. (NASDAQ:GILD), which is the primary FDA-approved twice-yearly preventive therapy for HIV; Nemluvio (nemolizumab) from Galderma (OTC:GALDY), concentrating on moderate-to-severe atopic dermatitis and prurigo nodularis; and Imkeldi (imatinib) from Shorla Oncology, a remedy for sure blood cancers and associated illnesses.
In line with Benzinga Pro, WBA inventory has gained over 10% up to now yr. Traders can acquire publicity to the inventory by way of Invesco S&P 500 Equal Weight Client Staples ETF (NYSE:RSPS).
Worth Motion: WBA inventory is buying and selling increased by 0.21% to $12.03 finally examine Tuesday.
Learn Subsequent:
